Prometheus Biosciences, Inc. (RXDX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in San Diego, CA, United States. Der aktuelle CEO ist Mark C. McKenna.
RXDX hat IPO-Datum 2021-03-12, 97 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $9.56B.
Prometheus Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and companion diagnostics for inflammatory bowel diseases (IBD). The company's lead candidate, PRA023, is a humanized monoclonal antibody currently in Phase IIa clinical trials for ulcerative colitis, Crohn's disease, and systemic sclerosis-associated interstitial lung disease. Prometheus maintains a robust pipeline including multiple therapeutic programs targeting different disease mechanisms in IBD and immune-mediated conditions, supported by strategic partnerships with leading pharmaceutical companies including Takeda, Dr. Falk Pharma, and Millennium Pharmaceuticals. Headquartered in San Diego, California, the company was incorporated in 2016 and formerly operated under the name Precision IBD, Inc. before rebranding to Prometheus Biosciences in October 2019.
